D.Investor, while the vast majority of studies show pseudoprogression typically means somewhat longer life with SOC, I'm referring to the profound impact pseudoprogressives would likely have had to the DCVax-L trial. You are well aware that Dr. Liau believes the very long (aka: more than 5 years, imho) lived patients from those earlier DCVax-L trials had MRI signals likely demonstrating pseudoprogression.
(Due to dosing improvements, a larger cross-section of representatives from different subtypes, and perhaps some manufacturing improvements, the phase III trial appears to be surprising researchers, imho.)
News 
Market Data 
Discover 
